Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234361 | 0.77 | PIK3CA (0.46) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL17869133 | 0.69 | ACSL1 (0.43) | ACACBHRH3 | |
| SCHEMBL17869135 | 0.69 | ACSL1 (0.43) | ACACBHRH3 | |
| SCHEMBL31234399 | 0.69 | PIK3CD (0.42) | PIK3CDPIK3R1PIK3CANAMPTPIK3CB | |
| SCHEMBL31234598 | 0.69 | PIK3CD (0.41) | PIK3CDPIK3R1PIK3CANAMPTPIK3CB | |
| SCHEMBL20137809 | 0.69 | BTK (0.47) | BTKPIK3CDACACBHRH3PIK3CA | |
| SCHEMBL20137808 | 0.69 | BTK (0.47) | BTKPIK3CDACACBHRH3PIK3CA | |
| SCHEMBL20137745 | 0.68 | HCRTR1 (0.47) | BTKPIK3CDACACB | |
| SCHEMBL20137746 | 0.68 | HCRTR1 (0.47) | BTKPIK3CDACACB | |
| SCHEMBL21802698 | 0.67 | MEN1 (0.44) | ACACBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | BTK 3063/4885PIK3CD 121/4885ACACB 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.